

Oncology Quality Results - MD Anderson Cancer Center at Cooper
January 2019 - June 2021

Description	Cooper 2019	Cooper 2020	Cooper 2021 through June	COC Standard	MDA Benchmark
Percentage of female patients >= age 18 who have their first diagnosis of breast cancer whose primary tumor is progesterone or estrogen receptor positive recommended for Tamoxifen or third generation aromatase inhibitor within 1 year of diagnosis.	100%	100%	100%	90%	90%
Percentage of female patients, age 18-69 who have their first diagnosis of breast cancer undergoing breast conservation surgery who receive radiation therapy within 1 year of diagnosis.	100%	100%	100%	90%	90%
Percentage of female patients, ages 18-69, who have their first diagnosis of breast cancer whose primary tumor is progesterone and estrogen receptor negative recommended for multi-agent chemotherapy within 4 months of diagnosis.	100%	100%	100%	90%	90%
Percentage of female breast cancer patients age 18 or older who were administered Bisphosphonates or Denosumab, in addition to chemotherapy or endocrine therapy, who have been diagnosed with bone metastasis.	100%	100%	Measure Retired	n/a	65-85%
Percentage of adult patients age 18 and older with invasive breast cancer that are HER2/neu positive who are administered Trastuzumab within 12 months of diagnosis.	100%	100%	100%	n/a	90%
Percentage of patients presenting with AJCC Stage 0, I, II, or III breast cancer, who underwent a needle biopsy to establish diagnosis of cancer preceding surgical excision/resection.	100%	100%	100%	80%	80%
Female patients with AJCC stage 0, I, or II, breast cancer that have undergone a total mastectomy who were offered or received a consultation for plastic surgery reconstruction.	100%	100%	100%	n/a	100%
Percentage of patients under the age of 80 with lymph node positive colon cancer for whom adjuvant chemotherapy is considered or administered within 4 months of diagnosis.	100%	100%	100%	n/a	n/a
Percentage of patients, greater than age 18 at diagnosis, who have primary colon tumors who have at least 12 regional lymph nodes removed and pathologically examined for resected colon cancer.	96%	100%	100%	85%	95%
Percentage of patients under the age of 80 with rectal cancer who were considered or administered adjuvant chemotherapy within 9 months of diagnosis.	100%	100%	Measure Retired	85%	89%
Percentage of patients with rectal cancer who were treated with neoadjuvant concurrent chemo radiation with Capecitabine or Infusional 5-FU.	100%	100%	Measure Retired	n/a	90%
Percentage of patients under the age of 80 with clinical or pathological rectal cancer having undergone surgical resection who were considered or administered radiation therapy within 6 months of diagnosis.	100%	100%	Measure Retired	85%	85%

Key
Green = Our results meet or exceed Commission on Cancer (COC) standard and The University of Texas MD Anderson Cancer Center (MDA) benchmark.

Cooper, COC and MDA data from January 2018 through September 2020 (most current data available).

